ARTLHealthcare · BiotechnologyARTL Stock Forecast: Artelo Biosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 1 Aug 2026 — in the weakest quartile.
ARTL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Artelo Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Artelo Biosciences, Inc. — and when they’d sell — is the membership.
ARTL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ARTL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2025 | Maxim Group | Downgrade | Hold | — |
| 8 Sept 2025 | D. Boral Capital | Downgrade | Hold | — |
| 26 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 July 2025 | D. Boral Capital | Upgrade | Buy | — |
| 11 June 2025 | D. Boral Capital | Downgrade | Hold | — |
| 6 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 1 Oct 2024 | EF Hutton | Initiates | Buy | $6.00 |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ARTL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Artelo Biosciences, Inc. (ARTL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- 0.7×
Cheaper than 75% of US stocks
Cheaper than 90% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −367.7%
- Return on assets
- −91.3%
- Dividend yield
- —
Higher than 3% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ARTL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARTL appears on the weeks it earns a place.
Frequently asked questions about ARTL stock
Is ARTL stock a buy right now?
Of the 1 analysts covering Artelo Biosciences, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artelo Biosciences, Inc. 15 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ARTL?
As at 1 Aug 2026, Artelo Biosciences, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
What is the ARTL stock forecast for 2030?
No analyst covering Artelo Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTL are extrapolating price history, which says nothing about the business.
How has ARTL stock performed over the past year?
Artelo Biosciences, Inc. returned -97.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Artelo Biosciences, Inc. do?
Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system.
About Artelo Biosciences, Inc.
Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating cancer-related anorexia and weight loss. ART12.11, a proprietary cannabidiol cocrystal with tetramethylpyrazine, targets anxiety, depression, post-traumatic stress disorder, epilepsy, insomnia, pain, and inflammation. ART26.12, a fatty acid binding protein 5 inhibitor, addresses chemotherapy-induced peripheral neuropathy, diabetic neuropathy, osteoarthritis pain, prostate and breast cancer, dermatologic conditions, and anxiety disorders. These candidates aim to fulfill unmet medical needs in oncology supportive care, neurology, psychiatry, and pain management. Founded in 2011 and headquartered in Solana Beach, California, Artelo Biosciences Inc. applies advanced scientific and regulatory expertise to advance its portfolio of innovative, proprietary therapies.
CEO Mr. Gregory D. Gorgas M.B.A. · 7 employees · United States · https://artelobio.com